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Abstract.
Background:The major genetic risk factor for late onset Alzheimer’s disease (AD) is theAPOE-4 allele. However,APOE-4
homozygosity is not fully penetrant, suggesting co-occurrence of additional genetic variants.
Objective: To identify genetic factors that, next to APOE-4 homozygosity, contribute to the development of AD.
Methods: We identified a family with nine AD patients spanning four generations, with an inheritance pattern suggestive
of autosomal dominant AD, with no variants in PSEN1, PSEN2, or APP. We collected DNA from four affected and seven
unaffected family members and performed exome sequencing on DNA from three affected and one unaffected family
members.
Results: All affected family members were homozygous for the APOE-4 allele. Statistical analysis revealed that AD onset
in this family was significantly earlier than could be expected based on APOE genotype and gender. Next to APOE-4
homozygosity, we found that all four affected family members carried a rare variant in the VPS10 domain of the SORL1 gene,
associated with APP processing and AD risk. Furthermore, three of four affected family members carried a rare variant in
the TSHZ3 gene, also associated with APP processing. Affected family members presented between 61 and 74 years, with
variable presence of microbleeds/cerebral amyloid angiopathy and electroencephalographic abnormalities.
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Conclusion: We hypothesize that next to APOE-4 homozygosity, impaired SORL1 protein function, and possibly impaired
TSHZ3 function, further disturbed A processing. The convergence of these genetic factors over several generations might
clarify the increased AD penetrance and the autosomal dominant-like inheritance pattern of AD as observed in this family.
Keywords: Alzheimer’s disease, APOE, genetics, penetrance, SORL1
INTRODUCTION
Alzheimer’s disease (AD) is a complex and het-
erogeneous neurodegenerative disease. AD incidence
increases with age, and about one third of the
population aged 85 years and older is estimated
to have AD [1]. AD is typically characterized by
deficits in short-term memory, language, praxis, and
visuospatial and executive functioning, eventually
resulting in global cognitive decline. Despite intense
research during past decades, the exact causes of
AD are not yet understood. The leading hypoth-
esis of AD pathogenesis is the amyloid cascade
hypothesis, which proposes that aberrant process-
ing of the amyloid- protein precursor (APP) leads
to increased production of amyloid- (A) peptide
in the brain cells (reviewed in [2]). In turn, A
peptides are misfolded and accumulate into pro-
tein aggregates, ultimately leading to the formation
of neurotoxic amyloid plaques that disrupt normal
cellular processes. Genetic mutations in autosomal
dominant AD are detected in genes involved in A
processing: the amyloid precursor protein (APP),
which is the source of A, and the presenilins
(PSEN1 and PSEN2) involved in APP-processing
[3–5].
Twin studies estimated that∼60–80% of late onset
AD risk is heritable with the remainder being envi-
ronmental (LOAD, age at onset >65 years) [6]. By
far the most important susceptibility gene for late
onset AD is the Apolipoprotein E (APOE) gene
[7]. Next to functions related with lipid and choles-
terol processing, the protein product of the APOE
gene, ApoE, is suggested to be involved in the clear-
ance of A from the brain (reviewed in [2]). The
APOE gene contains three common allelic variants
(APOE-ε2, APOE-ε3, APOE-ε4), which encode the
ApoE2, ApoE3, and ApoE4 protein isoforms. Opti-
mal A clearance efficiency has been suggested to
explain the neuroprotective nature of the ApoE2 iso-
form relative to the most common ApoE3 isoform,
whereas presumably, the impaired A clearance by
the ApoE4 isoform explains the increased AD risk for
APOE-ε4 allele carriers [2]. In fact, more than 30% of
the AD cases in the population can be attributed to the
APOE-4 allele (population attributable fraction),
whereas at most 8% of AD cases can be attributed
to any of the genes detected in a genome-wide asso-
ciation studies [8].
Carrying the APOE-4 allele predisposes for AD
in a dose-dependent manner: compared to non-
APOE-4 carriers, AD risk is increased 3–5 fold
for heterozygous APOE-4 carriers, and 10-15-fold
for homozygous APOE-4 carriers [9]. However,
despite this large effect size, the penetrance of APOE-
4 homozygosity is incomplete. The chance that
APOE-4 homozygotes develop AD before the age
of 85 years is 50% for males and 60% for females
[10]. Some APOE-4 homozygotes reach ages over
100 years while retaining their cognitive health [11].
This suggests that next to being homozygous for the
APOE-4 allele, additional genetic modifiers are nec-
essary for the development of AD. To our knowledge,
it has never been investigated whether other genetic
variants co-occur with APOE-4 homozygosity in
AD patients.
We identified a family with AD patients with a rel-
atively early onset of disease, spanning at least four
generations, with an inheritance pattern that suggests
autosomal dominant AD. DNA was available from
four affected and seven unaffected family members,
from the two youngest generations. We found that
all four genetically tested affected family members
were homozygous for the APOE-4 allele. There-
fore, this family provided the unique opportunity to
investigate additional genetic variants next to APOE-
4 homozygosity, which might have contributed to
AD. We describe the pedigree, the phenotype of
the affected family members, the outcome of whole
exome sequencing, and the segregation of the genetic
variants.
MATERIAL AND METHODS
Pedigree and participants
We describe a family comprising nine individuals
with AD symptoms who span four generations within
one pedigree (Fig. 1, Supplementary Table 1A): eight
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Fig. 1. Pedigree of family with four generations of AD patients. Black diamonds: Family members affected with AD; White diamonds:
non-affected family members at time of death or last screening; Grey diamond: no consent to reveal disease history; “W” in diamond: family
member included in whole exome sequencing; ‘n’ in a diamond, multiple family members merged and represented as one; AD [number],
Alzheimer’s disease with age at diagnosis; d [number], age at death. E4/E4, APOE-4 homozygosity; SORL1+, subject is positive for the
variant c.2012A>G in SORL1; TSHZ3+ subject is positive for the variant c.707C>T in TSHZ3; Grey text, DNA was not available for these
family members, we estimated the chances that an individual has a given APOE genotype, based on (i) frequency of genotype combinations
in the Dutch population, (ii) Mendelian inheritance patterns given the genotype distribution within the family structure and (iii) disease
status. The chances for APOE genotypes do not add up to 100% when (smaller) chances for other APOE genotypes remain (Supplementary
Table 1). Inferred chances of carrying of SORL1 and TSHZ3 genes are based on normal Mendelian inheritance patterns; Sex is not indicated
and the order of siblings is rearranged to avoid recognition of this family and individual family members. See Supplementary Table 1 for
list of genotype/phenotype data per-family member.
were diagnosed with AD, or were reported to have
symptoms of AD (0.2, I.1, I.3, I.4, II.1, II.3, II.4, and
II.6) and one individual had preclinical AD (III.1).
Multiple individuals did not present AD symptoms
at the time of observation (youngest individuals were
merged into III.4-III.5 to avoid recognition).
Four family members with (preclinical) AD and
seven of the unaffected family members (aged ≤60
years) consented to participate in this study (II.3 and
II.4 by consent of their proxies). Affected family
member II.1 consented to the use of his clinical data
for research purposes. Detailed clinical data were not
available for the affected family members of the first
generations (0.2, I.1, I.3, and I.4).
Two family members with AD (II.1 and II.6)
and the family member with preclinical AD (III.1)
visited the Alzheimer center at the VU Univer-
sity medical center (VUmc) in the Netherlands and
underwent extensive standardized diagnostic work-
up [12]. The other affected family members (II.3 and
II.4) were diagnosed elsewhere in the Netherlands.
All diagnoses of AD were based on the NINCDS-
ADRDA criteria as described by McKhann et al. [13].
Postmortem autopsy results of individual II.4 were
reviewed by our neuropathologist. The local medical
ethics committee of the VUmc approved the study.
We did not obtain consent to reveal disease history of
family member II.8.
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DNA availability
Using common procedures, DNA was isolated
from peripheral blood from three affected family
members (II.3, II.6, II.4) the family member with
preclinical AD (III.1), and the seven unaffected par-
ticipating family members (III.2, III.3, four family
members merged into III.4-5, and III.6).
APOE genotyping and imputation
For all participants with DNA available, APOE
genotyping was performed after genomic DNA iso-
lation from 7–10 mL EDTA blood, using a QIAxcel
DNA Fast Analysis kit (Qiagen, Venlo, The Nether-
lands). For the individuals comprising generation I
and two individuals from generation II, blood sam-
ples could not be collected. For individuals I.1, I.2,
II.1, and II.8 APOE genotypes were determined in
retrospect by estimating the posterior probability of
the possibleAPOE genotypes. To this end, we applied
Bayes theorem based on (i) the known APOE geno-
type combinations in generations II and III, (ii) the
population frequencies of APOE genotype combina-
tions in the Dutch population published by LASA
[14] (Supplementary Table 1B), and (iii) the chances
for developing dementia for all APOE-genotype com-
binations by age and gender published by Genin et al.
[10] (Supplementary Table 1C).
Analysis of AD penetrance in this family
In a Caucasian sample comprising >17,500 cases
and controls, Genin et al. evaluated the AD incidence
per APOE-genotype, across age at onset and gender
relative to baseline AD incidence [10]. These AD
incidence distributions across age allowed us to deter-
mine the a priori chance for any individual to develop
AD at a certain age given their APOE genotype and
gender. For each member of our family, the age at AD
onset can be seen as a p-value w.r.t. to empirical the
incidence distributions extracted from the Caucasian
cohort.
Persons who had not yet reached 60 years at last
check-up were excluded, as the chance to develop
AD before this age is very low. To account for
the unknown age at AD onset for several fam-
ily members, we determined a p-value by repeated
sampling from a uniform distribution of p-values
(truncated p-value approach [15]). We used both
Fisher’s approach and Stouffer’s approach to com-
bine p-values of all family members. Apart from
their genetic dependency (which we are testing),
we assume that development of AD is independent
between family members.
Variant detection: Exome sequencing of four
family members
DNA of three affected family members (II.3, II.6,
and III.1) and the oldest unaffected family member
(III.2) was exome sequenced in parallel with 400
AD patients from the Amsterdam Dementia cohort
(ADC) [12] who had been diagnosed with early
onset dementia. The exomes were captured by the
Nimblegen human exome v3 capture kit, and 100
bp paired-end sequencing reads were generated on
the Illumina HiSeq 2000 platform, according to
the manufacturer’s protocol. We sequenced to at
least 40x mean coverage to ensure sufficient read
depth for variant calling. Reads were mapped to the
human reference genome sequence (UCSC hg19)
using Burrows-Wheeler alignment [16]. Duplicate
read removal, local sequence realignment and base
quality recalibration were performed by Picard
(http://picard.sourceforge.net) and with GATK
(Genome analysis tool kit) [17]. Variants were called
using GATK haplotype caller, and filtered using the
variant filtration tool. For each variant we set the
filter to PASS if the variant complied with (I) GATK
quality score ≥50, (II) quality over depth ≥1.5, (III)
Strand bias ≤60, (IV) total variant read depth ≥5.0.
Variants were annotated and analyzed with Cartage-
nia (http://www.cartagenia.com/) using a filter tree
specifically designed to detect variants causative
for a trait with an autosomal dominant inheritance
pattern. Since we aimed to identify rare pathogenic
variants, we selected variants that (i) were absent
in the following databases: dbSNP138 (http://www.
ncbi.nlm.nih.gov/projects/SNP, build 138), the 1,000
genome project (http://www.1000genomes.org) or
the National Heart Lung Blood Institute Exome
Variant Server (EVS) (http://evs.gs.washington.
edu/EVS/); (ii) had a prevalence of ≤5% in the
whole Amsterdam Dementia cohort; (iii) were
heterozygote in the 3 affected family members; and
(iv) were localized in a gene listed in the OMIM
database (http://www.omim.org). The predicted
functional effects of the selected sequence vari-
ants were assessed by PolyPhen2 (http://genetics.
bwh.harvard.edu/pph2/), SIFT (http://sift.jcvi.org/),
Mutation Taster (http://www.mutationtaster.org),
and the combined annotation dependent deletion
(CADD) score [18]. Information about localization
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and conservation of the selected variants was
assessed by Uniprot (http://www.uniprot.org/uniprot/
Q92673), and Alumut visual (http://www.interactive-
biosoftware.com/alamut-visual/). Detected variants
were confirmed by Sanger sequencing, Also, loci
were genotyped in the all family members for whom
DNA was available.
RESULTS
Clinical description
Family member II.1 presented with complaints
of memory decline over the previous three years
at the age of 67. As a child, the family member
had suffered a skull fracture. The Mini-Mental State
Examination (MMSE) [19] score was 25/30, and neu-
ropsychological assessment showed impairment of
episodic memory. Routine blood analysis was nor-
mal, except for increased serum cholesterol levels.
Magnetic resonance imaging (MRI) showed mild
bilateral hippocampal atrophy (medial temporal lobe
atrophy grade 1 [20]), mild white matter hyperin-
tensities (WMH), (Fazekas grade 1 [21], and no
microbleeds. Electroencephalogram (EEG) revealed
a discordant low background rhythm of 6 to 7 Hz
with increased amounts of intermitting delta activ-
ity in the frontotemporal regions. Cerebrospinal fluid
(CSF) was not obtained. Based on these findings, the
diagnosis was mild cognitive impairment (MCI) [22].
At the age of 69, the MMSE was 21/30. Repeated
neuropsychological assessment showed progression
of memory impairment and impaired executive func-
tions. At this time, MRI showed biparietal atrophy,
with no progression of the hippocampal atrophy or
WMH. The clinical diagnosis was probable AD [13].
Disease progression was characterized by further
deterioration in all cognitive domains, including the
development of behavioral disturbances (loss of ini-
tiative and increased irritability). This family member
was admitted into a nursing home, suffered from
episodes of focal neurological deficits probably due
to recurrent strokes, and died at the age of 76 years.
This family member gave consent to his physician to
use his medical data for research purposes, but DNA
was not available.
Family member II.3 visited a geriatrician at a local
hospital at the age of 72 because of memory com-
plaints and fatigue for two years. This family member
had diabetes mellitus type 2, hypertension, and dys-
lipidemia, and had been treated for depression with
amitriptyline for over 20 years. MMSE was 26/30
with disorientation in time, and neuropsychologi-
cal testing showed impaired recall on memory tests.
Computed tomography (CT) imaging showed mild
diffuse cortical atrophy and aspecific hypodensities
in the brainstem and in the basal ganglia. No formal
diagnosis was made at that time. A second opinion by
another neurologist was obtained at the age of 74. At
this point, the family member reported the occurrence
of headaches, and scored 23/30 on the MMSE. Rou-
tine blood analysis and EEG were normal. MRI and
CSF analysis were not performed. The family mem-
ber was diagnosed with probable AD [13]. Diagnostic
DNA testing revealed no variants in PSEN1, PSEN2,
or APP. The family member died at the age of 78
years (cause unspecified).
Family member II.4 visited a local memory clinic
at the age of 70, because of progressive memory
complaints, which initiated at the age of 59 after a
head trauma. The family member had suffered from
bacterial meningitis at the age of 69. Neuropsycho-
logical testing showed impairments in concentration
and memory, disorientation in place, and dyscalcu-
lia. No additional investigations were performed. The
family member was diagnosed with probable AD
[13]. The patient died at the age of 74 years most
likely due to a heart attack. Postmortem examination
of the brain confirmed the diagnosis of severe AD
(Braak stage 6/6 for tau and Thal phase 5/5 for A
with extensive cerebral amyloid angiopathy (CAA)
type 1 [23] (Fig. 2).
Family member II.6 was evaluated at our memory
clinic at the age of 70 years because of the positive
family history of dementia. At this visit, this family
member reported no cognitive complaints, MMSE
was 30/30 and neuropsychological testing showed
no abnormalities except for some difficulties with
concentration. Routine blood analysis showed no
abnormalities. MR imaging displayed no hippocam-
pal atrophy (medial temporal lobe atrophy grade 0),
mild WMH (Fazekas grade 1), but a high number of
47 microbleeds, suggestive of CAA (Fig. 3). EEG
showed a remarkably decreased background pat-
tern with reactive alpha-theta activity till 8 Hz. CSF
analysis showed a decreased A level of 232 ng/L
(reference >550 ng/L), an increased total tau level
of 993 ng/L (reference ≤375 ng/L), and an increased
level of tau phosphorylated at threonine-181 (ptau)
of 123 (reference ≤52 ng/L)). Based on the clini-
cal examination, the family member was diagnosed
with subjective cognitive decline [24]. During the fol-
lowing years, the family member developed memory
68 E. Louwersheimer et al. / Rare Genetic Variant in SORL1 May Increase Penetrance of Alzheimer’s Disease
a b
Fig. 2. Immunohistochemistry in temporal cortex of subject II.4. a) Immunohistochemical staining for A reveals cerebral A angiopathy
(black arrow), classical plaques (arrow head), and diffuse plaques (white arrow) in the temporal cortex (10x obj.); b) Immunohistochemical
staining for tau (mab AT8) reveals neuropil threads, (pre)tangles (arrow), and neuritic plaques (arrow head) in the temporal cortex (10x obj.).
Fig. 3. Baseline MR imaging of subject II.6. Cerebral MRI imag-
ing of subject II.6 at age 70 showing several microbleeds (arrows).
T2 weighted image.
complaints, loss of initiative, and sleeping problems.
At the age of 74 years, MMSE was 29/30, and
neuropsychological testing showed disturbances in
episodic memory. MRI showed no progression of
WMH, but the number of microbleeds had increased
to 58. Repeated EEG displayed progressive slowing
with theta activity of 7 Hz next to dominant posterior
rhythms of 8 Hz. The family member was diagnosed
with MCI. The family member was diagnosed with
probable AD by a local geriatrician at the age of 82,
with a MMSE score of 21 out of 30.
Family member III.1 presented at our memory
clinic at 58 years with memory complaints, and self-
reported difficulties with organizing and planning.
This family member was treated for diabetes mel-
litus, hypertension, and dyslipidemia. MMSE score
was 29/30, performance on neuropsychological test-
ing was normal, and MRI showed no abnormalities.
EEG was disturbed with a normal alpha background
pattern of 9 Hz, but with early intermitting left pre-
dominant temporal theta activity. CSF concentrations
showed a mildly decreased A level of 549 ng/L (ref-
erence >550 ng/L) and increased tau level of 435 ng/L
(reference ≤375 ng/L) and ptau level of 68 (ref-
erence ≤52 ng/L). Pittsburgh compound (PiB)-PET
showed increased A binding in all cortical areas.
F18-fluorodeoxyglucose (FDG)-PET showed a nor-
mal pattern of glucose metabolism. Based on clinical
evaluations, the diagnosis was subjective cognitive
decline. The abnormal AD biomarkers indicated pre-
clinical AD, with a high likelihood of underlying AD
pathophysiology [25]. Over the next four years, the
family member remained clinically stable.
Generation 0 and I: Family member I.2 died of
cancer at age 55. Family member 1.3, a sibling of
I.2, was reported to have dementia onset at 61. Fam-
ily member 1.4, also a sibling of I.2, was reported to
have cognitive decline prior to death at age 73. One
of their parents (generation 0) was reported to have
dementia symptoms suggestive of AD at age 80, Fam-
ily member I.1 (partner from I.2) died at the age of
85 years from a heart attack and was reported to have
had dementia with AD characteristics. For these fam-
ily members, no formal diagnosis was available at the
time and no DNA was secured.
Unaffected family members in generation III: The
seven unaffected family members (III.2, III.3, III.4-5,
and III.6) for whom DNA was available were aged 47
to 60 years and self-reported no cognitive complaints.
Their partner and/or a close relative confirmed
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absence of signs of cognitive impairment. No for-
mal cognitive tests were performed in these family
members.
APOE genotype distribution in family structure
All affected family members with for whom DNA
was available (II.3, II.4, II.6, III.1) were homozy-
gous for the APOE-ε4 allele. Of the seven unaffected
family members from generation III for whom DNA
was available, two were genotyped APOE-ε4/ε4, four
were APOE-ε3/ε4, and one was APOE-ε3/ε3 (Sup-
plementary Table 1A, Fig. 1).
Given the frequency of all APOE genotype com-
binations in the Dutch population, disease status of
each family member by age, and the APOE geno-
types for all individuals in generations II and III, we
estimated a 65% chance that individuals I.1 and I.2
are APOE-ε3/ε4 and APOE-ε4/ε4; and we estimated
a 29% chance that individuals are both APOE-ε3/ε4
(grey text in Fig. 1). Chances for other possible geno-
types were negligible (Supplementary Table 1D).
Likewise, we estimated a 76% chance that the APOE
genotype of individual II.1, who was diagnosed with
AD at 69, was APOE-ε4/ε4: and a 22% that it was
APOE-ε3/ε4; chances for other possible genotypes
were negligible (Supplementary Table 1E). Individ-
ual II.8 has an 87% chance of being APOE-ε3/ε4 and
a 12% chance of being APOE-ε3/ε3 (Supplementary
Table 1F). Together, this provides support that this
family included at least three generations ofAPOE-ε4
homozygotes.
Chances of developing AD in this family:
A statistical analysis
We evaluated the AD incidence in this family
w.r.t. empirical age at onset distributions extracted
from a Caucasian cohort, given APOE-genotype and
gender [10] (Supplementary Table 1C). The age
of AD onset in this family was significantly ear-
lier than expected: p = 0.0001 and p = 0.00006 using
respectively Fisher’s method and Stouffer’s method
of combining p-values. P-values remain significant
when we use the age at diagnosis, suggesting that
the finding is robust: p = 0.0290 and p = 0.0094 using
Fisher’s method and Stouffer’s method respectively
(Supplementary Table 1A).
Of note, the high incidence of AD may have
stimulated family members to visit our hospital for
cognitive testing. This may have introduced a bias
at the age at AD onset level that we cannot account
for. However, further family research revealed that
I.3 and I.4 (two siblings of I.2, who died of cancer at
age 55) were reported to have dementia at relatively
early ages at onset irrespective of family bias (61 and
73 years, respectively).
Exome sequencing outcome
To investigate whether additional genetic variants
occurred next to APOE-ε4 homozygosity, we per-
formed exome sequencing in two siblings with AD
(II.3, II.6), in one family member with preclinical
AD (III.1) and in the eldest participant without cog-
nitive complaints hitherto (III.2), all homozygous for
the APOE-ε4 allele. Exome sequencing revealed no
mutations in the PSEN1, PSEN2, and APP genes in
any of the family members.
We detected 16 variants that passed filtering, sev-
eral of which were rare and predicted to have a
deleterious effect on protein function (Supplemen-
tary Table 2). Two of these occurred in a gene
that might be functionally associated with amy-
loid processing or AD: (i) the missense variant
c.2021A>G, p.Asn674Ser, in exon 14 of the sortilin
related receptor 1 (SORL1) gene (NM.003105.5),
and (ii) c.707 C>T, p.Thr236Met, in exon 2 of
the teashirt zinc ﬁnger homeobox 3 (TSHZ3) gene
(NM.020856.2). The coverage of SORL1 and TSHZ3
captured with the exome kit was similar to the median
read depth over the whole exome.
This SORL1 variant was present in all three
affected family members and the family member with
preclinical AD, and in four unaffected family mem-
bers (aged <60 years). The variant was not detected
in any other subject in the Amsterdam Dementia
cohort. One study detected the variant in a 63-year-
old healthy female (control group n = 1938, MAF
<0.001) [26], and the ExAC database reports only one
heterozygous carrier of this variant (MAF <0.00001).
The variant locus is at a highly conserved glycosyla-
tion site in the VPS10 domain of SORL1 (Fig. 4), it
has a CADD score of 23.6, and it is considered dele-
terious by PolyPhen and Mutation Taster (although
not by SIFT).
The p.Thr236Met missense variant in TSHZ3 was
detected in two of the three family members with AD,
in the family member with preclinical AD and in one
unaffected family member, who was also homozy-
gous for APOE-ε4 but did not carry the SORL1
variant. This TSHZ3 variant is located in a highly
conserved amino acid, has a CADD score of 27.0 and
is predicted to be deleterious by PolyPhen, Mutation
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Fig. 4. p.Asn674Ser in the SORL1 protein. SORL1 is located on chromosome 11q23.2-q24.2 and codes for a 250-kDa membrane protein
with seven distinct domains. Blue (dark grey), extracellular domains; green (light grey), intracellular domain; arrow, the p.Asn674Ser variant
we identified in this family; P, Pro-peptide; VPS10, vacuolar protein sorting domain 10; LDLR-B, LDL-receptor class B repeats; EGF,
epidermal growth factor precursor type repeat; LDLR-A, LDL-receptor class A repeats; FN-III, fibronectin type-III repeats; IC, intracellular
component; LDL, low density lipoprotein. The figure is based upon information from Uniprot (http://www.uniprot.org/uniprot/Q92673),
transcript NM 003105.
Taster, and SIFT. The variant was reported in 47 indi-
viduals in the ExAC database (MAF <0.001).
DISCUSSION
We describe a family with an inheritance pattern
suggestive of autosomal dominant AD of which all
affected family members tested were homozygous for
the APOE-4 allele. The age at AD onset was sig-
nificantly earlier than expected, based on the APOE
genotypes and gender of family-members, suggesting
that next to a high load of APOE-ε4, this family is rel-
atively enriched with other AD-associated elements.
Whole exome sequencing revealed two additional
variants co-inherited with APOE-4 homozygosity
that might disturb A processing: a rare missense
variant leading to p.Asn674Ser in the SORL1 protein
and a rare missense variant leading to p.Thr236Met
in the TSHZ3 protein. We speculate these SORL1
and TSHZ3 variants increased the penetrance of AD
in this family. Without APOE-4 homozygosity, nei-
ther variants may reach full AD penetrance, as can
be observed in the pedigree where several APOE-4
heterozygous or APOE-4 negative family members
carry the SORL1 and/or TSHZ3 gene variants with-
out having the disease. It should be noted however,
that these family members are still young, and may
develop AD at a later age, such that we cannot exclude
the possibility that either variant confers full AD pen-
etrance. For the same reason we cannot (yet) identify
the effect of APOE-4 gene dosage, by analyzing to
what extent impaired SORL1 and/or TSHZ3 modu-
lates AD penetrance in a background of heterozygous
APOE-4. Moreover, this family carried several addi-
tional rare genetic variants, some of which were
predicted to have a deleterious effect on protein
function. Although these variants map in genes that
are currently not associated with AD, we cannot a
priori rule out that they modulate AD susceptibility
in this family.
TSHZ3 may modulate Aβ processing
The rare variant detected in TSHZ3 is predicted
to have a damaging effect on protein function by
all effect predictor algorithms, and has a relatively
high CADD score of 27. Although evidence is lim-
ited, this rare variant might complicate A processing
since the TSHZ3 protein has been found to bind to
FE65, an adaptor protein that can modulate APP
trafficking and/or processing [27]. TSHZ3 downreg-
ulates Caspase 4, which is involved cell death induced
by cytotoxic APP peptides [28–30]. However, more
evidence is needed to link disturbed TSHZ3 protein
function to AD.
Impaired SORL1 increases Aβ production
In sharp contrast with TSHZ3, evidence has accu-
mulated that impaired SORL1 function associates
with AD: common genetic polymorphisms in the
SORL1 locus were associated with AD in a genome-
wide association studies [31], disruptive variants
were only detected in AD cases and not in con-
trols [26] and rare pathogenic SORL1 variants were
found to increase the risk for early onset AD by five-
fold [32].
Functional studies suggested that the SORL1 sort-
ing receptor has a dual function: (i) SORL1 binds
APP and prevents it from processing into A [33],
and (ii) SORL1 binds newly synthesized extracellular
A and targets it to the lysosome for degradation [34].
To exert these functions, SORL1 has two important
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protein domains: an APP-binding complement
type repeat domain, and an A-binding VPS10
domain [33].
The p.Asn674Ser variant in SORL1 that we
detected in this family affects a highly conserved
N-glycosylation site in the VPS10 domain, which is
important for proper protein folding and for protein-
protein interaction [33]. Previously, variants that map
in the VPS10 domain (p.Glu270Lys, p.Ala528Thr)
were associated with impaired retrograde sorting of
APP and enhanced A production when expressed
in cells [35], suggesting that a wild-type VPS10
domain is essential for proper A processing. We
speculate that the p.Asn674Ser change detected in
this family may at disrupt the A-binding capac-
ity of SORL1, resulting in less efficient lysosomal
degradation of A [34].
Combined effect of APOE-4 homozygosity,
impaired SORL1 and impaired TSHZ3
Experimental studies suggest that the proteins
encoded by the APOE and SORL1 genes function-
ally interact [36]. By binding to the complement
type repeats of the SORL1 protein, ApoE4 reduced
the APP-binding-capacity of SORL1 [37]. Further-
more, overexpression of SORL1 increases the uptake
of extracellular A in an ApoE-isoform-dependent
manner, most efficiently in the presence of the 4
isoform [36]. Therefore, the clearance of A is
expected to be more dependent on SORL1 expres-
sion in APOE-4 carriers than in individuals with no
APOE-4 alleles. A combination of homozygous or
heterozygous ApoE4 and dysfunctional SORL1 may
therefore lead to abnormal increases in extracellular
A loads, which may underlie the neurodegenerative
processes in this family.
Effect of the genotype on phenotype
Homozygous APOE-4 carriers typically present
with an amnestic phenotype, however the AD pheno-
type of the five affected family members for whom
detailed clinical data were available, was heteroge-
neous. The age at onset differed between affected
family members and ranged between 61 and 74 years,
which fits with the relatively early age of disease
onset associated with APOE-4 homozygosity [38].
Homozygous APOE-4 and disrupted SORL1 are
both associated with CAA, presumably as a result of
the less effective A clearance [39–41]. Indeed, two
family members with AD had extensive microbleeds
and CAA, while two others remained free of
microbleeds.
Both APOE and SORL1 are involved in choles-
terol metabolism/transport, and APOE-4 carriers
have been found to have increased cholesterol levels
[42, 43]. Indeed, three affected family members were
diagnosed with hypercholesterolemia in this family.
Likewise, the EEG pattern of APOE-4 allele carrier-
patients shows a greater decrease of alpha activity
than non-APOE-4 carrier-patients [44, 45]. How-
ever, in this family, neither microbleeds/CAA, hyper-
cholesterolemia or EEG patterns cosegregated with
APOE-4 homozygosity and/or the SORL1 variant.
Conclusion
We hypothesize that the convergence of multiple
genetic factors that disturb the A processing path-
ways over several generations results in an autosomal
dominant like inheritance pattern of AD in this family.
Extracellular A load might be abnormally increased
as a result of the concerted effects of (i) ineffective
clearance of extracellular A from the brain by the
ApoE4 protein isoform, and (ii) impaired uptake of
extracellular A for lysosomal degradation due to a
disturbed VPS10 domain of the SORL1 protein. It is
possible that a disturbed TSHZ3 function might have
further contributed to impaired APP regulation, but
compared to ApoE4 and SORL1, the evidence for an
association of disrupted TSHZ3 with AD is currently
very limited. Moreover, other genetic variants that
were left undetected with our analysis strategy might
have further influenced disease penetrance.
Given these findings, the currently unaffected fam-
ily member who is homozygous for APOE-4 and
who carries the SORL1 variant may be at the high-
est risk to develop AD. Follow-up of this family in
the future will resolve these speculations. We expect
that this polygenic model, possibly involving other
genetic variants, might also explain autosomal dom-
inant inheritance patterns in other APOE-4 positive
families.
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